Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy.
about
Treatment of dyslipidemia in patients with type 2 diabetes.Risk management in the treatment of type 2 diabetes with pioglitazoneMetabolic effects of a conversion from rosiglitazone to pioglitazone in Native American patients with type 2 diabetes.A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetesA review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications.Cardiovascular disease prevention in patients with type 2 diabetes: The role of oral anti-diabetic agents.Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies.Effects of pioglitazone on lipid and lipoprotein metabolism.Third-line agent selection for patients with type 2 diabetes mellitus uncontrolled with sulfonylureas and metformin.Use of pioglitazone in the treatment of diabetes: effect on cardiovascular riskRedefining the role of thiazolidinediones in the management of type 2 diabetesSystematic review: Evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values.Effects of cardiovascular lifestyle change on lipoprotein subclass profiles defined by nuclear magnetic resonance spectroscopy.The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus.Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity or mortality? No.Thiazolidinediones and cardiovascular risk - a question of balance.Therapies for diabetic dyslipidaemia.Effects of pioglitazone and vildagliptin on coagulation cascade in diabetes mellitus--targeting thrombogenesis.Effect of addition of either sitagliptin or pioglitazone in patients with uncontrolled type 2 diabetes mellitus on metformin: A randomized controlled trialThe cardiovascular safety of rosiglitazone
P2860
Q34499472-149AC545-A4D3-4772-932E-DDD8968BB1ECQ34620706-9CE37005-AF23-495D-AF67-90BE3B35163FQ36054778-3989CD80-C5D2-4605-BA76-B61E185EE606Q36536205-86578D61-C2B3-42AA-A326-BD54234B9C05Q36596873-5E8F839F-B78A-4BC9-ACEA-6369033F3133Q36679594-CB35DC9E-DE0E-4E65-958C-B2B3658C6CC0Q36844378-F13589DD-4971-4AF2-9C72-28938B50B77EQ36909527-D41EB856-FE33-4968-B280-898EE768E5F9Q37117876-09296EEE-3CCD-4A28-99FF-2F0BBDCEDE05Q37151347-B5F1388C-391A-4718-A490-ABAFC083538BQ37167551-A856DBF1-5FF4-488F-8A76-7E5B0B4ACC9BQ37182703-2EF4B5CE-FD61-468C-8813-ED8469FCCE0AQ37268440-035C36D3-7EE6-40B5-943E-71B018A54E52Q37395321-D1204365-4C20-431D-B5A6-75BAA8D86DC0Q37624301-4680BF3D-93AD-496A-A3E2-ADC783E2FB52Q37777027-CF4E5F44-2AFE-4095-BCD4-EAF7990075EEQ37825945-BFC580C9-1CDC-4758-A340-BA2FEDAFFEF7Q38077284-3407A176-D5F1-49D0-89BF-412678A95A09Q40358908-C6AC8882-CA71-4A49-B0ED-C7B4E9DCAF36Q54152623-7BD2590E-CB04-49F1-A856-C4BF0EE3CCC4
P2860
Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Effects of pioglitazone on lip ...... tinuing stable statin therapy.
@en
Effects of pioglitazone on lip ...... tinuing stable statin therapy.
@nl
type
label
Effects of pioglitazone on lip ...... tinuing stable statin therapy.
@en
Effects of pioglitazone on lip ...... tinuing stable statin therapy.
@nl
prefLabel
Effects of pioglitazone on lip ...... tinuing stable statin therapy.
@en
Effects of pioglitazone on lip ...... tinuing stable statin therapy.
@nl
P2093
P2860
P921
P356
P1476
Effects of pioglitazone on lip ...... tinuing stable statin therapy.
@en
P2093
Alfonso T Perez
Mark S Kipnes
Mehmood A Khan
Paulos Berhanu
Penny R Fleck
Robert C Spanheimer
Seleshi Demissie
Stuart F Kupfer
P2860
P356
10.3132/DVDR.2006.005
P407
P577
2006-05-01T00:00:00Z